GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients
27 mai 2015 06h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - May 27, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced top line results from the GS-4774 Phase 2 study in patients with chronic hepatitis B on long term...
GlobeImmune Announces First Quarter 2015 Results and Corporate Highlights
14 mai 2015 06h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - May 14, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced its first quarter 2015 financial results and corporate highlights."We are pleased with the progress...
GlobeImmune Announces Opening of Randomized Phase 2 Chordoma Trial at National Cancer Institute
22 avr. 2015 06h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - April 22, 2015) - GlobeImmune, Inc. today announced that a randomized Phase 2 clinical trial designed to investigate the safety and efficacy of GI-6301 in combination...
GlobeImmune Announces Program Updates and Financial Results for Full Year 2014
17 mars 2015 06h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - March 17, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) today provided an update on the Company's business and clinical programs, and announced financial results for the full...
GlobeImmune to Present at the 27th Annual ROTH Conference
02 mars 2015 06h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - March 02, 2015) - GlobeImmune, Inc.,
(NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 27th Annual ROTH...
GlobeImmune to Present at the 17th Annual BIO CEO & Investor Conference
03 févr. 2015 06h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - February 03, 2015) -
GlobeImmune, Inc.,
(NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 17th Annual BIO CEO...
GlobeImmune Announces Third Quarter 2014 Financial Results
12 nov. 2014 06h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - November 12, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM), today announced its third quarter 2014 financial results and corporate highlights."Following the completion of...
Updated Chordoma Data From Phase 1 Study of GI-6301 Presented at 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting
17 oct. 2014 06h30 HE
|
GlobeImmune, Inc.
BERLIN, GERMANY--(Marketwired - October 17, 2014) - GlobeImmune, Inc., today announced that updated results from eleven chordoma patients in the GI-6301 Phase 1 trial were presented at the 2014 CTOS...
GlobeImmune to Present at the 13th Annual BioInvestor Forum
30 sept. 2014 07h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - September 30, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 13th Annual BioInvestor...
GlobeImmune to Present at the 21st Annual NewsMakers in the Biotechnology Industry Investment Conference
18 sept. 2014 07h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - September 18, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 21st Annual BioCentury...